NASDAQ · RMD
Healthcare · Medical - Instruments & Supplies
$229.94
Down-$22.89 (-9.05%)
Updated Oct 31, 2026, 2:13 AM
SID Score
7.1/10
Composite research score
Smart Money
58/100
Neutral
Price performance · RMD
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
RMD closed at $229.94 after 21 trading sessions, up 5.05% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $246.56 | $248.045 | $228.33 | $229.94 | 3.47M |
| Oct 29, 2026 | $253.57 | $254.27 | $249.60 | $252.83 | 1.45M |
| Oct 28, 2026 | $248.50 | $252.20 | $247.79 | $250.17 | 1.02M |
| Oct 27, 2026 | $250.33 | $251.765 | $247.70 | $250.80 | 936.66K |
| Oct 26, 2026 | $251.48 | $254.99 | $249.44 | $253.20 | 1.07M |
| Oct 23, 2026 | $251.83 | $255.565 | $248.72 | $252.86 | 1.03M |
| Oct 22, 2026 | $245.41 | $253.62 | $244.18 | $253.06 | 1.73M |
| Oct 21, 2026 | $243.94 | $248.60 | $243.94 | $246.20 | 899.29K |
| Oct 20, 2026 | $241.98 | $246.48 | $240.50 | $245.50 | 1.25M |
| Oct 19, 2026 | $235.50 | $240.32 | $235.50 | $239.77 | 932.29K |
| Oct 16, 2026 | $241.54 | $242.575 | $237.87 | $238.97 | 2.55M |
| Oct 15, 2026 | $238.16 | $242.63 | $237.90 | $242.23 | 1.11M |
| Oct 14, 2026 | $235.58 | $237.06 | $232.7638 | $235.29 | 1.02M |
| Oct 13, 2026 | $236.59 | $236.86 | $233.15 | $235.04 | 892.03K |
| Oct 12, 2026 | $231.74 | $235.98 | $230.08 | $234.60 | 1.05M |
| Oct 9, 2026 | $226.54 | $231.36 | $226.415 | $230.05 | 1M |
| Oct 8, 2026 | $225.79 | $226.875 | $223.04 | $226.73 | 651.15K |
| Oct 7, 2026 | $222.27 | $228.75 | $221.83 | $225.98 | 1.13M |
| Oct 6, 2026 | $223.90 | $225.23 | $219.96 | $220.69 | 972.85K |
| Oct 5, 2026 | $218.44 | $223.72 | $218.44 | $222.86 | 976.46K |
| Oct 2, 2026 | $221.66 | $223.73 | $218.03 | $218.89 | 898.89K |
The latest Smart Investors Daily articles mentioning RMD.
Company
Market Activity
Research & News
RMD research
Company profile and research snapshot.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | Citigroup | Neutral | — |
| Oct 30, 2026 | Wells Fargo | Equal-Weight | — |
| Oct 30, 2026 | RBC Capital | Outperform | — |
| Oct 30, 2026 | Keybanc | Overweight | — |
| Sep 15, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 23, 2026
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Yahoo · Oct 23, 2026
ResMed has launched the AirTouch F40 CPAP mask in the U.S., a fabric-cushioned, minimalist design that connects into its myAir and AirView platforms and is intended to support comfort, adherence and easier fitting for obstructive sleep apnea patients. The ability for existing AirFit F40 users to switch to the new ComfiSoft fabric cushion without a full refit highlights how ResMed is trying to lift adherence and resupply activity while keeping patients inside its connected ecosystem. We will...
Yahoo · Oct 22, 2026
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 19, 2026
Latest addition to Resmed’s growing fabric mask portfolio combines a soft, breathable fabric cushion with a minimalist design for greater comfort and choiceSAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced the U.S. launch of AirTouch F40, the newest addition to its growing portfolio of fabric continuous positive airway pressure (CPAP) masks. Designed for peop
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RMD.
